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Abstract
Background: Patients with type 2 diabetes mellitus and heart failure have adverse clinical outcomes, but the
characteristics and prognosis of those with undiagnosed diabetes in this setting has not been established.
Methods: In total, 400 patients admitted consecutively with acute heart failure were grouped in three glycaemic
categories: no diabetes, clinical diabetes (previously reported or with hypoglycaemic treatment) and undiagnosed
diabetes. The latter was defined by the presence of at least two measurements of fasting plasma glycaemia ≥ 7
mmol/L before or after the acute episode. Group differences were tested by proportional hazards models in all-
cause and cardiovascular mortality during a 7-year follow-up.
Results: There were 188 (47%) patients without diabetes, 149 (37%) with clinical diabetes and 63 (16%) with
undiagnosed diabetes. Patients with undiagnosed diabetes had a lower prevalence of hypertension, dyslipidaemia,
peripheral vascular disease and previous myocardial infarction than those with clinical diabetes and similar to that
of those without diabetes. The adjusted hazards ratios for 7-year total and cardiovascular mortality compared with
the group of subjects without diabetes were 1.69 (95% CI: 1.17-2.46) and 2.45 (95% CI: 1.58-3.81) for those with
undiagnosed diabetes, and 1.48 (95% CI: 1.10-1.99) and 2.01 (95% CI: 1.40-2.89) for those with clinical diabetes.
Conclusions: Undiagnosed diabetes is common in patients requiring hospitalization for acute heart failure. Patients
with undiagnosed diabetes, despite having a lower cardiovascular risk profile than those with clinical diabetes,
show a similar increased mortality.
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Introduction
Type 2 diabetes has an estimated prevalence of 20-40%
in heart failure patients, being an independent risk fac-
tor not only for the development of heart failure [1-6]
but also for increased morbidity and mortality [7-13].
On the other hand, several studies have highlighted
the frequent underdiagnosis of diabetes in the general
population and in high cardiovascular risk patients
[14-17]. The few reports on t h ep r e v a l e n c eo fu n d i a g -
nosed diabetes in patients with stable chronic heart fail-
ure suggest it could affect 10% of patients [18,19].
Most of the studies that have quantified the adverse
outcomes of patients with diabetes and heart failure
have been limited to patients with a known diagnosis of
diabetes. Previous reports have outlined the prognostic
importance of undiagnosed diabetes in patients with dif-
ferent cardiovascular diseases [16,20-22]. In patients
with established coronary artery disease, undiagnosed
diabetes has been proven to be a highly significant and
independent predictor of cardiovascular and all-cause
mortality [21,22]. Patients with heart failure requiring
hospital admission for an acute episode represent a
high-risk population for adverse outcomes [23-26]. In
this group of patients, mortality is higher than in those
with chronic stable heart failure and, thus, identification
of patients with an increased risk within this group who
could benefit from more aggressive therapeutic interven-
tions could help improve their poor outcomes. However,
the risk associated with undiagnosed diabetes in patients
with acute heart failure has not been described. Thus,
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acute heart failure was to determine the prevalence and
characteristics of patients with undiagnosed diabetes
and its impact on all-cause and cardiovascular mortality
during a 7-year follow-up in comparison with patients
with and without clinical diabetes.
Patients and Methods
Patients and baseline measurements
An observational study of a retrospective cohort of all
patients admitted to the cardiology department of Hos-
pital del Mar (Barcelona, Spain) with the diagnosis of
acute heart failure was carried out between January 1st,
2000 to December 31st, 2002. All patients with acute
heart failure as one of the two first discharge diagnoses
were included. Discharge records were reviewed and the
following data was gathered: demographic and clinical
characteristics, cardiovascular risk factors, previous dia-
betes treatment, cause of heart failure, left ventricular
ejection fraction measured by echocardiography, chronic
renal failure, peripheral vascular disease, previous myo-
cardial infarction or stroke, plasma biochemical para-
meters at the time of admission [glycemia, creatinine,
hemoglobin and glycosylated hemoglobin (HbA1c)] and
drug therapy at discharge. Before the year 2002 HbA1c
was only determined in patients with a clinical diagnosis
of diabetes at admission. From January 2002 onwards,
HbA1c was systematically measured in all subjects
admitted with acute heart failure. Thus, data on HbA1c
for individuals without clinical diabetes was available in
only 35% of the cases. Investigators obtained data from
medical and laboratory records and did not participate
in patient treatment and management.
To identify undiagnosed diabetes, we had access to
clinical diagnosis, laboratory data and pharmaceutical
treatment registered in all primary health care centres in
the province of Barcelona and in the autonomous com-
munity of Catalonia. Laboratory data for blood samples
drawn in acute situations are specified as “emergency
laboratory”, as these blood samples are processed in a
different laboratory, and thus these samples were
excluded for diabetes diagnosis. For blood samples
drawn in primary health care centres at routine check-
up visits, patients are given specific instructions regard-
ing fasting a minimum of 8 hours, as per protocol. In
patients presenting hyperglycaemia during admission,
but no prior glucose values in the range of diabetes, we
also reviewed the laboratory data of the year after dis-
charge to rule out recent-onset diabetes.
Diabetes was diagnosed according to 1997 American
Diabetes Association criteria [27], and patients were
classified in three categories: 1) clinical diabetes mellitus,
when the diagnosis was specified in medical reports or
patients were being treated for diabetes (dietary advice,
oral drugs or insulin); 2) undiagnosed diabetes mellitus,
without clinical diabetes but with two or more outpati-
ent fasting plasma glucose concentrations ≥ 7 mmol/L;
and 3) no diabetes mellitus, who did not meet the cri-
teria for clinical or undiagnosed diabetes.
Mortality data
Mortality rates and causes of death were monitored
e v e r yy e a ru n t i lJ a n u a r y2 0 0 9b ys y s t e m a t i cr e v i e wo f
hospital records and death certificates from the Death
Registry Office of Catalonia, coded according to the
International Classification of Diseases (ICD) 9th edi-
tion. Cardiovascular death was defined by ICD-9 codes
390-459. Mean follow-up was 7.5 year (range: 6-9 years).
The study was approved by the local Ethics Committee.
Statistical analysis
Quantitative variables were described by mean ± stan-
dard deviation (SD) and compared by Student’st w o -
tailed T test. Qualitative variables were described by fre-
quencies and percentages and were compared using
Chi-Square test or Fisher’se x a c tt e s t ,a sa p p r o p r i a t e .
Logistic regression model was performed to assess speci-
fic characteristics of patients with undiagnosed diabetes.
Survival univariate analysis was estimated with the
Kaplan-Meier method and differences were tested with
a log rank test. Multivariate survival analysis was per-
formed with Cox proportional hazards model, to deter-
mine the independent contributions of the three
glycaemic categories to all-cause and cardiovascular
mortality after adjusting for age, sex, comorbidities
(smoking, hypertension, dyslipidaemia, stroke, chronic
renal failure, peripheral vascular disease, previous myo-
cardial infarction) hemoglobin concentrations, left ven-
tricular ejection fraction a n ds t a n d a r dh e a r tf a i l u r e
medication (loop diuretic/thiazide, beta-blocker, angio-
tensin converting enzyme-inhibitor/angiotensin receptor
blocker). Values of p < 0.05 were considered significant.
Statistical analysis was conducted using SPSS 15.0
(SPSS, Inc., Chicago, Illinois).
Results
Baseline characteristics
416 patients were initially included and 16 cases (3.9%)
were excluded from analyses for being lost to follow-up.
The final study group included 400 patients, 203 men
and 197 women, with a mean age of 71.5 ± 10 years.
The distribution of patients within glycaemic categories
was: clinical diabetes 37%, undiagnosed diabetes 16%
and no diabetes 47%. Regarding diabetes therapy pre-
vious to admission in patients with clinical diabetes,
30% received dietary advice only, 48% took oral antidia-
betic agents and 30% used insulin. Baseline characteris-
tics of patients are shown in Table 1. Clinical diabetes
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sion, dyslipidaemia, peripheral vascular disease and pre-
vious myocardial infarction. Patients with undiagnosed
diabetes had a prevalence of these comorbidities similar
to that of those without diabetes. Patients with diabetes,
both clinical and undiagnosed, had more hospital admis-
sions due to acute heart failure in the previous year;
however, no differences in left ventricular ejection frac-
tion were found among groups. Furthermore, the fre-
quency of heart failure with systolic dysfunction
(ejection fraction less than 40%) was also similar among
groups (51.5% in no diabetes, 45.8% in undiagnosed dia-
betes and 52.3%, in clinical diabetes, p = 0.67). Regard-
ing laboratory parameters at admission, hemoglobin
concentrations were significantly lower in patients with
diabetes, both clinical and undiagnosed, compared to
those without diabetes. Fasting glycaemia was higher in
subjects with clinical diabetes than in those with undiag-
nosed diabetes. HbA1c was 62 ± 16 mmol/mol (7.8 ±
1.5%) in patients with clinical diabetes, 44 ± 12 mmol/
mol (6.2 ± 1.1%) in subjects with undiagnosed diabetes
and 40 ± 16 mmol/mol (5.8 ± 1.5%) in those without
diabetes (p < 0.001 among groups). Cardiovascular drug
therapy at discharge was similar in the three groups,
although beta-blockers were more commonly prescribed
in patients with clinical diabetes.
When comparing subjects with undiagnosed diabetes
with those without diabetes in multivariate logistic
regression analysis, only hospital admission for heart
failure in the previous year was more frequent in those
with undiagnosed diabetes [risk ratio of 1.37 (95% confi-
dence interval (CI): 1.16 to 1.49)].
Mortality during follow-up
The 7-year incidence of total and cardiovascular mortal-
ity in relation to baseline glycaemic categories is shown
in Table 2. There were 262 (65.2%) deaths, of which 192
were cardiovascular. The Kaplan-Meier survival curves
illustrate higher risk for all-cause and cardiovascular
death in patients with clinical and undiagnosed diabetes
(Figure 1).
Cox proportional hazards models comparing patients
with undiagnosed and clinical diabetes with those with-
out diabetes are depicted in Table 2. All-cause mortality
risk was similar in subjects with undiagnosed and clini-
cal diabetes and significantly higher than in those with-
out diabetes, with an adjusted risk ratio of 1.69 (95% CI:
1.17-2.46) and 1.48 (95% CI: 1.10-1.99), respectively.
Patients with undiagnosed and clinical diabetes also
showed an increased risk for cardiovascular death, with
an adjusted risk ratio of 2.45 (95% CI: 1.58-3.81) and
2.01 (95% CI: 1.40-2.89), respectively. When patients
Table 1 Baseline characteristics of patients according to glycemic status at hospitalization
No diabetes (n = 188) Undiagnosed diabetes (n = 63) Clinical diabetes (n = 149) p-value
Age (years) 71.1 (11.4) 72.7 (10.4) 71.4 (7.7) 0.568
Male (%) 100 (53) 30 (49) 73 (48) 0.627
Cardiovascular risk factors
Smoking (%) 37 (19.8) 7 (11.3) 19 (12.6) 0.113
Hypertension (%) 129 (69) 44 (71) 126 (83.4) 0.007
Dyslipidemia (%) 40 (21.3) 17 (27) 56 (37.6) 0.002
Previous cardiovascular disease
MI (%) 39 (21) 18 (29) 51 (34) 0.024
Stroke (%) 20 (11) 7 (11) 23 (15) 0.434
Peripheral vascular disease (%) 16 (9) 4 (6) 31 (21) 0.001
HF ischemic etiology (%) 65 (35) 25 (40) 80 (54) 0.002
LVEF % (SD) 46 ± 18 47 ± 18 45 ± 18 0.771
Last-year HF Admission (%) 18 (9.6) 14 (22.6) 31 (20.7) 0.006
Biochemical parameters at admission
Fasting glucose mmol/L (SD) 5.5 ± 0.8 6.6 ± 1.5 7.8 ± 2.7 < 0.001
Creatinine μmol/L (SD) 116.7 ± 73.4 120.2 ± 49.5 114 ± 55.7 0.817
Haemoglobin g/L (SD) 0.131 ± 0.020 0.124 ± 0.023 0.125 ± 0.019 0.015
HF drug therapy at discharge
ACEI/ARA II (%) 122 (65.2) 39 (62.9) 97 (64.2) 0.943
b-blockers (%) 52 (27.8) 13 (21) 56 (37.1) 0.041
Diuretics (%) 163 (87.2) 52 (83.9) 126 (83.4) 0.597
Spirinolactone (%) 55 (29.4) 23 (37.1) 47 (31.1) 0.527
ACEI, angiotensin-converting enzyme inhibitors; ARA-II, angiotensin-2 receptor antagonists; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial
infarction.
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apy, only those on insulin treatment showed signifi-
cantly increased all-cause mortality (figure 2), with an
adjusted risk ratio of 2.11 (95% CI: 1.48-3.00). This sub-
group of patients also had the highest risk of death from
a cardiovascular cause when compared with subjects
without diabetes [adjusted risk ratio 2.73 (95% CI: 1.76-
4.24)], table 2.
Discussion
A high proportion of subjects with diabetes were pre-
viously undiagnosed, consequently, the prevalence of
diabetes in patients with acute heart failure is higher
than previously recognized, occurring in more than half
of the patients studied. Furthermore, the study estab-
lished that patients with undiagnosed diabetes, despite
having less cardiovascular risk factors and comorbidities,
had a similar increased mortality as that of subjects with
clinical diabetes.
Prevalence of undiagnosed diabetes
The prevalence of diabetes in this study was higher than
previously reported, which ranged from 23% to 43%
[10-13]. This wide range reflects the diverse criteria
used to identify patients with diabetes and the differ-
ences between heart failure populations analyzed. Most
studies and registries of heart failure have only included
patients with clinical diabetes, based on medical history
Table 2 Adjusted hazards ratio (HR) for all-cause and cardiovascular death at 7-year follow-up in heart failure patients
with undiagnosed and clinical diabetes compared with those without diabetes
All-cause death p value Cardio-vascular death p value
No. of events (%) HR*(95% CI) No. of events (%) HR*(95% CI)
No-diabetes (n = 188) 105 (55.9) 1 (reference) 56 (29.8) 1 (reference)
Undiagnosed diabetes (n = 63) 45 (72.6) 1.69 (1.17-2.46) 0,006 36 (58.1) 2.45 (1.58-3.81) 0,001
Clinical diabetes (whole group) 112 (74.2) 1.48 (1.10-1.99) 0,009 84 (55.6) 2.01 (1.40-2.89) 0,006
Clinical diabetes (treatment)
Diet alone (n = 43) 28 (63.6) 1.38 (0.9-2.13) 0,129 20 (45.5) 1.87 (1.09-3.18) 0,026
Oral drugs (n = 48) 34 (70.8) 1.33 (0.89-1.98) 0,221 22 (45.8) 1.49 (0.89-2.47) 0,096
Insulin (n = 58) 50 (84.7) 2.11 (1.48-3.00) 0,005 42 (71.2) 2.73 (1.76-4.24) < 0,001
*Adjusted for age, sex, hypertension, dyslipidemia, smoking, previous stroke, previous myocardial infarction, peripheral vascular disease, hemoglobin and plasma
creatinine concentrations.
Figure 1 Kaplan-Meier survival curves for all cause (A) and cardiovascular (B) mortality* according to glycaemic category (no-diabetes,
clinical diabetes and undiagnosed diabetes). No-DM: no-diabetes mellitus; CDM: clinical diabetes mellitus; UDM: undiagnosed diabetes
mellitus. *Data are adjusted for age, sex, comorbidities, haemoglobin concentrations, left ventricular ejection fraction and standard heart failure
medication.
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20% of the population with diabetes following dietary
advice only, as well as those with undiagnosed diabetes.
In the present study, systematic “review” of fasting
blood glucose levels resulted in an undiagnosed diabetes
prevalence of 16%, which means that 30% of diabetes
cases were not detected. This figure is consistent with
the undiagnosed diabetes prevalence reported in subjects
with established cardiovascular disease [16,17,21,22]. In
patients with stable chronic heart failure, Kistorp et al
[18] described a clinical diabetes prevalence of 21%,
while that of undiagnosed diabetes was 6%. Further-
more, most diabetes prevalence studies in heart failure
have been conducted in outpatient clinics, while the pre-
sent study only included those requiring hospitalization
for acute decompensated heart failure. In the large US
ADHERE registry of patients with acute decompensated
heart failure, 40% of the patients had clinical diabetes
[13], similar to the 37% prevalence reported in the pre-
sent study. Therefore, the prevalence of diabetes in
heart failure patients seems to be increased in those
requiring hospitalization for acute decompensation.
Long-term mortality of patients with undiagnosed
diabetes
Patients with undiagnosed diabetes were 1.69 times
(95% CI: 1.16-2.35) more likely to die during follow-up
than those without diabetes. The excess in mortality
appears to be mainly due to increased cardiovascular
mortality. The present study demonstrates this relation-
ship in a cohort of heart failure patients and the results
are similar to those found in patients with coronary
artery disease [21,22]. The association between undiag-
nosed diabetes and increased mortality existed despite
the relative preservation of left ventricular ejection frac-
tion. This finding is in agreement with Suskin et al [19],
who found undiagnosed diabetes to be related to worse
symptomatic status, but not worsening of left ventricular
ejection fraction.
It is known that increased cardiovascular mortality in
type 2 diabetes is related, at least in part, with comor-
bidities such as hypertension, dyslipidaemia and other
cardiovascular diseases. However, in the present study,
patients with undiagnosed diabetes had a mortality risk
similar to those with clinical diabetes despite having
lower fasting blood glucose and HbA1c levels at admis-
sion and a lower prevalence of hypertension, dyslipidae-
mia, coronary heart disease and peripheral vascular
disease. Thus, the increased mortality in subjects with
undiagnosed diabetes must be attributed to factors other
than those usually associated with diabetes.
In this respect, previous studies showed heart failure
to be an insulin-resistant state that may predispose to
diabetes [28,29]. Amato et al [30] demonstrated in a
longitudinal study that chronic heart failure was asso-
ciated with an increased incidence of non-insulin-
Figure 2 Kaplan-Meier survival curves for all cause (A) and cardiovascular (B) mortality* according to glycaemic status and diabetes
treatment (no-diabetes, undiagnosed diabetes, clinical diabetes on diet, clinical diabetes on oral drugs and clinical diabetes on
insulin). No-DM: no-diabetes mellitus; CDM: clinical diabetes mellitus; UDM: undiagnosed diabetes mellitus. *Data are adjusted for age, sex,
comorbidities, haemoglobin concentrations, left ventricular ejection fraction and standard heart failure medication.
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dence supports the idea that insulin resistance pro-
gresses within the natural course of heart failure [31].
Based on these findings, undiagnosed diabetes identified
in the present study could reflect a “hyperglycemia”
developed in patients with more severe heart failure, as
reflected by its association with more previous hospitali-
zations for acute heart failure. Therefore, rather than
being the cause of poor clinical outcomes, undiagnosed
diabetes could represent a prognostic marker of heart
failure severity.
To our knowledge, this is the first study to describe
the prevalence of undiagnosed diabetes in patients with
acute heart failure and to analyze the impact of this
condition on long-term mortality. The clinical relevance
of our findings is that more attention should be paid in
diagnosing glucose abnormalities in patients admitted
with heart failure, as this simple, cost-effective interven-
tion allows identification of high-risk patients who could
benefit from more aggressive therapeutic interventions.
Our study has some limitations that need to be
acknowledged. The retrospective collection of clinical
data precluded gathering information that might have
been used to more accurately assess the relationship
between diabetes and mortality in patients with heart
failure, such as diabetes duration, complete data on
HbA1c and microangiopathic complications. However,
the retrospective collection of clinical data allowed eva-
luation of the impact of undiagnosed diabetes; a pro-
spective study would have prevented this analysis on
ethical grounds. Furthermore, the cohort of the present
study was restricted to patients with acute decompen-
sated heart failure that required hospitalization, and
thus the data observed here cannot be extrapolated to
the whole heart failure population. Finally, we do not
have information regarding the possible diagnosis and
treatment of diabetes during the seven-year follow-up
period in those patients with undiagnosed diabetes at
the time of admission, and thus can not analyze poten-
tial differences. Therefore, further studies will be needed
to ascertain whether early diagnosis and treatment of
diabetes can improve clinical outcomes in these patients.
Conclusions
Undiagnosed diabetes is common in patients requiring
hospitalization for acute heart failure. Patients with
undiagnosed diabetes, despite having a lower cardiovas-
cular risk profile than those with clinical diabetes, show
a similar increased mortality. These findings underscore
the importance of identifying glucose abnormalities in
heart failure patients. This simple and cost-effective
intervention permits identification of high-risk patients
w h oc o u l db e n e f i tf r o ma g g r e s s i v et h e r a p e u t i c
interventions.
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